CLINICAL TRIAL

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-03-03
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Psyence Australia Pty Ltd

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Clinical Trial Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09 Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-23 The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.CNS spectrums · 2024-12-01 Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21 Perceptions of psychedelic-assisted therapy among Black Americans.Journal of mood and anxiety disorders · 2023-12-01 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24